The FDA requires data from single and repeated-dose general toxicity and carcinogenicity preclinical studies that begin after December 17, 2016 to be submitted electronically in Standard for Exchange of Nonclinical Data (SEND) format.

We will present at the joint exhibition with KOBE Biomedical Innovation Cluster at the 3rd Regenerative Medicine Expo & Conference Japan held at INTEX Osaka, on February 15 [Wed] to 17 [Fri], 2017.

May 10, 2016: GLP measurement using the ultrasensitive Erenna immunoassay begins

Shin Nippon Biomedical Laboratories, Ltd., received the highest level of the L-Boshi award and certification from the Japanese Ministry of Health, Labour, and Welfare for being a woman-friendly workplace.